本文由小咖机器人翻译整理

期刊来源：Nat Med

原文链接：https://doi.org/10.1038/s41591-024-02826-w

摘要内容如下：

我们报道了抗CD19嵌合抗原受体（CAR）T细胞免疫疗法治疗非霍奇金B细胞淋巴瘤3个月后发生的T细胞淋巴瘤（TCL）。TCL是在肺癌手术后从胸部淋巴结诊断出来的。TCL表现出CD8+细胞毒性表型和JAK3变体，而CAR转基因非常低。在CART输注前的血液中和肺癌中鉴定出低水平的T细胞克隆。为了评估商业CART（CD19，BCMA）后继发性原发性恶性肿瘤（SPM）的总体风险，我们分析了在宾夕法尼亚大学接受治疗的449例患者。中位随访时间为10.3个月，16名患者（3.6%）患有SPM。实体和血液系统恶性肿瘤的中位发病时间分别为26.4和9.7个月。预计5年累积发病率为15.2%（实体瘤）和2.3%（恶性血液病）。总体而言，观察到一例TCL，表明CART后发生TCL的风险较低。

英文原文如下：

Abstracts

We report a T-cell lymphoma (TCL) occurring three months after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy for non-Hodgkin B-cell lymphoma. The TCL was diagnosed from a thoracic lymph node upon surgery for lung cancer. The TCL exhibited CD8+ cytotoxic phenotype and a JAK3 variant, while the CAR transgene was very low. The T-cell clone was identified at low levels in the blood before CART infusion and in the lung cancer. To assess the overall risk of secondary primary malignancy (SPM) after commercial CART (CD19, BCMA), we analyzed 449 patients treated at the University of Pennsylvania. At a median follow-up of 10.3 months, 16 patients (3.6%) had SPM. Median onset time was 26.4 and 9.7 months for solid and hematological malignancies, respectively. The projected 5-year cumulative incidence is 15.2% for solid and 2.3% for hematological malignancies. Overall, one case of TCL was observed, suggesting a low risk of TCL post-CART.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。

现在购买可享受最大优惠（买一年送三个月，买两年送一年），2024年2月10日起将不再享有该优惠。